Print Page | Sign In | Join Today
News & Press: Company News

Cavion’s T-Type Calcium Channel Modulator CX-8998 Shown to Supress Seizures

Monday, November 5, 2018  
Share |

Cavion, a clinical stage biotechnology company developing novel therapeutics for neurological diseases, announced that their first-in-class T-type calcium channel modulator CX-8998 significantly suppressed seizures in two translational animal models of absence epilepsy. CX-8998 was more effective than the commonly prescribed anti-epileptic drug ethosuximide in reducing absence seizures in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), a highly predictive model of absence epilepsy. In the GAERS rats, CX-8998 showed near complete suppression of seizure activity (99% reduction in both number and cumulative duration of spike wave discharges) at 10 mg/kg, a well-tolerated dose that results in human-achievable drug concentrations. In contrast, ethosuximide suppressed 60% of seizure activity at exposures associated with the optimal human dose. The poster being presented today in the Anticonvulsant and Antiepileptic Therapies Session (289.21) of the Society for Neuroscience Annual Meeting held in San Diego, CA, also described CX-8998’s preclinical efficacy against seizure as tested previously in the WAG/Rij rat model.

“Based on this promising preclinical research, Cavion is conducting T-WAVE, an open-label Phase 2a clinical trial assessing the safety, tolerability and efficacy of CX-8998 in adolescents and adults with absence seizures,” said Margaret Lee PhD, Cavion’s Senior Vice President, Preclinical and Translational Sciences. “T-WAVE will study whether CX-8998 can significantly reduce seizures and improve outcomes for humans who have not achieved satisfactory response to currently available therapies.”

“CX-8998 is one of the most powerful compounds that we have seen in the GAERS model for absence seizures to date – virtually eliminating them. The analysis was conducted using EEG, the most rigorous assessment of seizures possible,” said Corinne Roucard, CEO of SynapCell, exclusive provider of the predictive translational GAERS model for more than 13 years.


Our Sponsors

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected